Skip to content
value.today

Apricus Biosciences

APRIUnlisted company
No market cap data
Compare
World rank
—
no current market cap
Revenue
$2 M
For year ending December-2023
Net income
$-38 M
-1721.8% margin
SEC filing
Employees
—

Apricus Biosciences in brief

Apricus Biosciences is an unlisted company in the Biotechnology industry, based in San Diego, USA. It was founded in 1987. In the year to December 2023 it had sales of $2 M and a net loss of $38 M.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Apricus Biosciences

Apricus Biosciences, Inc. is a San Diego–based biopharmaceutical company advancing innovative medicines in urology and rheumatology.

Apricus Biosciences' first product, Vitaros®, has been approved in Europe and Canada for the treatment of erectile dysfunction Other compounds in development include: low testosterone, rheumatology, sexual dysfunction, pain,

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Apricus Biosciences timeline

5 events, 1987–2019
  1. 1987
  2. 🏁
    · approximate
    Founded
  3. 1997
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2010
  6. ✎
    Renamed Apricus Biosciences, Inc.
    Formerly Nexmed Inc.
  7. 🔔
    · approximate
    Initial public offering on Nasdaq as APRI
  8. 2019
  9. ✎
    Renamed Seelos Therapeutics, Inc.
    Formerly Apricus Biosciences, Inc..

Events of Apricus Biosciences from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Apricus Biosciences

Acquisitions and changes
Delisted: the exchange removed its shares from listing (Form 25-NSE) on 4 April 2025.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-1721.8%
Operating margin
-1840.9%
Return on equity
—
Liabilities / assets
718.3%
Net debt
$11M
Revenue growth
+478.9%
R&D / revenue
1369.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2016: revenue $6M, net income $-7M$6MFY16Fiscal year ending Dec 2017: revenue —, net income $0M—FY17Fiscal year ending Dec 2018: revenue —, net income $-3M—FY18Fiscal year ending Dec 2019: revenue $0M, net income $-51M$0MFY19Fiscal year ending Dec 2020: revenue —, net income $-19M—FY20Fiscal year ending Dec 2021: revenue —, net income $-66M—FY21Fiscal year ending Dec 2022: revenue —, net income $-74M—FY22Fiscal year ending Dec 2023: revenue $2M, net income $-38M$2MFY23
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2023$2M—$-41M$-38M-1721.8%
Dec 2022——$-71M$-74M—
Dec 2021——$-62M$-66M—
Dec 2020——$-19M$-19M—
Dec 2019$0M—$-30M$-51M-13489.5%
Dec 2018——$-3M$-3M—
Dec 2017——$-11M$0M—
Dec 2016$6M—$-14M$-7M-129.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2023$-24M——$-7.73—
Dec 2022$-62M——$-20.74—
Dec 2021$-49M——$-0.73—
Dec 2020$-21M——$-0.43—
Dec 2019$-19M——$-2.52—
Dec 2018$-2M——$-1.13—
Dec 2017$-11M$0M$-11M$0.81—
Dec 2016$-13M$0M$-13M$-1.15—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Mar 2023: revenue $1M, net income $-13M$1MMar ’23Three months to Jun 2023: revenue $0M, net income $-30M$0MJun ’23Three months to Sep 2023: revenue $0M, net income $11M$0MSep ’23Three months to Dec 2023 (from the annual report): revenue $1M, net income $-5M$1MDec ’23Three months to Mar 2024: revenue $1M, net income $-3M$1MMar ’24Three months to Jun 2024: revenue $0M, net income $2M$0MJun ’24

Latest quarter to Jun 2024: revenue $0M (+11.8% on a year earlier), net income $2M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of Apricus Biosciences with the US Securities and Exchange Commission.

Annual results

Revenue
$2 M
Operating income
$-41 M
Net income
$-38 M

For year ending December-2023 · source: SEC filing

Balance sheet

Total assets
$5 M
Total liabilities
$39 M
Total equity
$-34 M

As of December-2023

Insider trading at Apricus Biosciences#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
27
since
$100 K$0Nov 2023: bought $100 K (1 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $100 K (1 trades), sold $0 (0 trades)Dec
Bought (open market)Sold (open market)Hover a month for the totals
Apricus Biosciences: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Michael Joseph GolembiewskiChief Financial OfficerGrant or award+417$1.100$45986,869Form 4
filed Raj MehraSee Remarks, DirectorBuy+75,757$1.320$100 K185,142Form 4
filed Michael Joseph GolembiewskiChief Financial OfficerBuy+83,000$1.210$100 K86,450Form 4
filed Michael Joseph GolembiewskiChief Financial OfficerGrant or award+12,500$0.620$8 K103,487Form 4
filed Michael Joseph GolembiewskiChief Financial OfficerGrant or award+12,500$0.670$8 K90,987Form 4
filed Daniel J. O'ConnorDirectorBuy+16,000$0.610$10 K16,000Form 4
filed Margaret DalesandroDirectorBuy+35,000$0.600$21 K35,000Form 4
filed Raj MehraSee Remarks, DirectorBuy+66,667$0.850$57 K3.28 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Apricus Biosciences#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Buybacks, Q4 2023
$0M
Q4 2023

Stock splits: 1-for-33.33 reverse split ; 1-for-10 reverse split

Bankruptcy filing: (8-K)

Apricus Biosciences share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2023Q4 2023$0M
Q3 2023Q3 2023$0M
Q2 2023Q2 2023$0M
Q1 2023Q1 2023$1.2M
Q4 2015Q4 2015$0M
Q3 2015Q3 2015$0M
Q4 2014Q4 2014$0M
Q3 2014Q3 2014$0M
Q4 2013Q4 2014$0M
Q3 2013Q3 2014$0M

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Apricus Biosciences scorecard#

Passes 0 of the 8 checks that could be worked out. Fiscal year 2023.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-7.73 vs -20.74Diluted EPS -7.73 in fiscal 2023 against -20.74 the year before (report's currency).
    • ✗Net income higher than five years earlier-$38 M-$38 M in fiscal 2023 against -$3 M in 2018.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$38 MNet income -$38 M in fiscal 2023.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2023.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.1×Current ratio 0.14 at the end of fiscal 2023.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-506.2×Operating income -506.2 times interest in fiscal 2023.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2023.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year38.2%Diluted shares up 38.2% in fiscal 2023.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Apricus Biosciences: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Apricus Biosciences: statements by fiscal year
PeriodTrendFY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015FY 2014to Dec 31, 2014
Income statement
Revenue2.2——00.400.55.84.89.3
Cost of revenue———————0.50.90.9
Gross profit———————1.93.98.3
Research and development30594711230.6r3.55.9r1521
General and administrative1312157.87.62.6r7.27.8r1111
Operating expenses43716219303.2r1114r2531
Operating income−40−71−62−19−30−3.2r−11−14r−21−23
Interest expense and finance costs0.10.01.60.20.00.10.11.00.80.1
Other non-operating income (expense)2.6−2.6−4.4−0.3−22−0.3r−1.16.0r2.30.1
Income tax————————00
Income from continuing operations—————−9.2−12−7.7−19−22
Income from discontinued operations—————−0.0120.200.7
Net income attributable to shareholders−38−74−66−19−51−3.5r0.3−7.4−19−22
Earnings per share, basic-7.73-20.74r-0.73-0.43-2.52-1.13r0.81r-1.15r-3.83r-0.55
Earnings per share, diluted-7.73-20.74r-0.73-0.43-2.52-1.13r0.81r-1.15r-3.83r-0.55
Shares, weighted average (basic)4.93.5r91———————
Shares, weighted average (diluted)4.93.5r9145203.1r0.4r6.5r5.0r40
Balance sheet
Cash and cash equivalents3.0167916100.0r0.3r2.13.911
Receivables0.8——————0.50.50.7
Inventory———————0.80.50.3
Other current assets1.67.14.71.80.80.0r0.30.2r1.1r0.6
Current assets5.4238317110.2r6.63.66.2r13
Property, plant and equipment—————0.00.10.2r1.31.4
Right-of-use (leased) assets0.00.10.00——————
Total assets5.4238417110.2r6.74.77.8r15
Accounts payable163.61.71.90.82.2r0.10.8r1.60.9
Current liabilities39258.37.4114.9r1.61116r6.9
Lease liabilities (non-current)—0.0—0——————
Total liabilities39332615114.9r2.31218r13
Retained earnings−253−215−141r75r−56−4.8r−316−316−309−290
Shareholders' equity−34−11572.6−0.0−4.7r−1.3r−7.5−9.91.9
Total liabilities and equity5.4238417110.2r6.74.77.8r15
Shares outstanding1.2r3.6r10655273.1r0.5r7.75.0r44
Cash-flow statement
Depreciation and amortization—————0.00.10.1r0.30.2
Share-based compensation4.05.18.32.00.50.0r1.11.71.21.7
Cash from operating activities−24−62−49−21−19−1.6r−11−13−23−18
Capital expenditure——————0−0.0−0.3−0.6
Cash from investing activities——————00.3−0.3r−0.5
Debt repaid——————−6.6———
Shares issued——988.9r170r1115r115.9
Shares bought back−1.2———————0−0.0
Cash from financing activities11−1.611226301.4r2.51115r7.9
Exchange-rate effect on cash—————————0
Change in cash−13−63635.410−0.2r4.2−1.8−7.5−10
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Apricus Biosciences#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Bankruptcy or receivershipFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Bankruptcy or receivership 1 · Delisting notice 3 · Restructuring 1 · Directors and officers 1 · Material agreement 11 · Agreement ended 1 · Unregistered share sale 4 · Shareholder rights changed 4 · Bylaws or fiscal year changed 4 · Shareholder vote 3

Apricus Biosciences: events reported to the SEC
FiledWhat happenedFiling
Bankruptcy or receivership8-K
Shareholder vote8-K
Delisting notice8-K
Shareholder vote8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Material agreement8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Delisting noticeRestructuringDirectors and officersMaterial agreement8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Shareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Material agreementAgreement ended8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Material agreementUnregistered share sale8-K
Delisting notice8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 22, 2024

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Apricus Biosciences
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2017$4 MNo. 2$2 to $10 million9equity, optionsSEC
Sep 2016$4 MNo. 1$2 to $10 million2optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Apricus Biosciences#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2012–2024
Latest
—
2024-04-30
Apricus Biosciences: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
2016············—
2012············—
Apricus Biosciences: latest layoffs
AnnouncedPeopleKindWhereSource
33% of workforceRestructuring planSEC 8-K“On April 30, 2024, the Company announced a reduction in its workforce that affected approximately 33% of its current employees (the “RIF”), along with a reduction in working hours …”Filing
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Apricus Biosciences compares in Biotechnology

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Apricus Biosciences🇺🇸————
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending December-2023
Balance sheet:
As of December-2023
Profile updated:
Nov 14, 2026

Figures from SEC filing, Wikidata, Wikipedia, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Apricus Biosciences? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Apricus Biosciences's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Apricus Biosciences? Suggest a correction